Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;30(11):4573-8.

Analysis of the cytotoxic activity of carboplatin and gemcitabine combination

Affiliations

Analysis of the cytotoxic activity of carboplatin and gemcitabine combination

Sisi Wang et al. Anticancer Res. 2010 Nov.

Abstract

Aim: To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects.

Materials and methods: The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry.

Results: Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance.

Conclusion: Different doses and administration schedules affect the antitumor effect of carboplatin/gemcitabine combination that may have clinical significance in the treatment for bladder cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The anti-tumor activity of carboplatin, gemcitabine or in combination. A and B: Dose-dependent cytotoxic effects of 5637 cells exposed to carboplatin (A) or gemcitabine (B). C. Dose-effect curves for the carboplatin/gemcitabine combinations. 5637 cells were treated with: gemcitabine for 4 h followed by carboplatin for 4 h (square); carboplatin for 0.5 h followed by carboplatin plus gemcitabine for 3.5 h (circle); carboplatin for 4 h followed by gemcitabine for 4 h (triangle). Data are means ± SD of three independent experiments (each with samples in triplicate). *p<0.05, ***p<0.001. D. CI Plot. CI values are plotted as a function of the fractional inhibition (Fa) from 0.10 to 0.97. The CI values of <0.9 (below the lower dash line), =0.9–1.1, and <1.1 (above the upper dash line) represent synergism, additivity and antagonism, respectively.
Figure 2
Figure 2
Characteristic DNA histograms of 5637 cells treated with carboplatin, gemcitabine or in combination. The progressive cell cycle changes were observed after 24, 48 and 72 h of treatment, as compared with the untreated controls. Content of DNA is represented on the X axis; number of cells counted is represented on the Y axis.

Similar articles

Cited by

References

    1. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;2000;18:3068–3077. - PubMed
    1. Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias A. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced with bladder carcinoma: phase II study of the hellenic cooperative oncology group. Urology. 2004;2004;64:479–484. - PubMed
    1. Bajetta E, Stani SC, De Candis D, Zaffaroni N, Zilembo N, Cortinovis D, Aglione S, Mariani L, Formisano B, Bidoli P. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. European Society for Medical Oncology. 2003;2003;14:242–247. - PubMed
    1. Hudson E, Lester JF. Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. Eur J Cancer Care. 2010;2010;19:324–328. - PubMed
    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;2002;346:92–98. - PubMed

Publication types

MeSH terms